...
首页> 外文期刊>Pharmaceutical research >A novel method for imaging in vivo degradation of poly(L-glutamic acid), a biodegradable drug carrier.
【24h】

A novel method for imaging in vivo degradation of poly(L-glutamic acid), a biodegradable drug carrier.

机译:成像成像的一种新方法体内聚(L-谷氨酸),一种可生物降解的药物载体。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

PURPOSE: To develop an L-PG-based imaging probe suitable for assessing the degradation of L-PG in vivo. MATERIALS AND METHODS: Conjugates of L-PG and a near-infrared fluorescence (NIRF) dye, NIR813, were characterized with regard to quenching efficiency and degradability by cathepsin B (CB) and other proteases. The kinetics of L-PG-NIR813's degradation and its degradation in orthotopic human U87/TGL glioma in nude mice after intravenous injection was assessed using NIRF optical imaging (n = 3). RESULTS: The fluorescence signal from L-PG-NIR813 was efficiently quenched and activated at NIR813 loadings of 8-10%. Upon exposure to CB, the fluorescence intensity of L-PG-NIR813 increased 10-fold. L-PG-NIR813 was also degraded by another cysteine protease cathepsin L, but not by MMP-2, cathepsin E, cathepsin D, and plasmin. A selective CB inhibitor blocked the fluorescence activation. After intravenous injection, the degradation of L-PG-NIR813 was visualized primarily in the liver, which peaked at 4 h postinjection. Activation of L-PG-NIR813 but not D-PG-NIR813 was clearly seen in U87/TGL tumors. CONCLUSION: Our results indicate that L-PG-NIR813 may be used to monitor the in vivo degradation of L-PG-based polymeric drugs, and that this agent may prove useful in noninvasive imaging of protease activity, particularly that of cysteine proteases.
机译:目的:开发一种基于L-PG的成像探针,适用于评估体内L-PG的降解。材料与方法:对L-PG和近红外荧光(NIRF)染料NIR813的结合物进行了组织蛋白酶B(CB)和其他蛋白酶的猝灭效率和可降解性表征。使用NIRF光学成像(n = 3)评估了静脉注射后裸鼠中L-PG-NIR813的降解动力学及其在原位人类U87 / TGL胶质瘤中的降解。结果:L-PG-NIR813发出的荧光信号在NIR813的8-10%负载下被有效淬灭并激活。暴露于CB后,L-PG-NIR813的荧光强度增加了10倍。 L-PG-NIR813也被另一半胱氨酸蛋白酶组织蛋白酶L降解,但未被MMP-2,组织蛋白酶E,组织蛋白酶D和纤溶酶降解。选择性CB抑制剂阻止了荧光激活。静脉注射后,主要在肝脏中观察到L-PG-NIR813的降解,在注射后4小时达到峰值。在U87 / TGL肿瘤中清楚地看到了L-PG-NIR813的激活,而不是D-PG-NIR813的激活。结论:我们的结果表明,L-PG-NIR813可用于监测基于L-PG的聚合药物的体内降解,并且该药物可证明对蛋白酶活性特别是半胱氨酸蛋白酶的无创成像有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号